Minneapolis-based OrthoCor's launch of a new knee brace that uses electromagnetic pulse therapy to alleviate pain and speed healing could serve as a medical technology tutorial.
Safety and effectiveness? Check.
U.S. Food and Drug Administration approval? Check.
Ample angel investment and a growing roster of impressed orthopedic doctors and happy patients? Check, check and check.
But there remains a speed bump along the way to OrthoCor Medical Inc. raking in oodles of cash for its Active Knee System: Medicare and widespread insurance company reimbursement. Until that comes, OrthoCor lingers on the verge of becoming big.
"We are right on the cusp," said OrthoCor President and CEO John Dinusson, who added that "some" insurers are paying for the $695 device. "We are basically educating them on why they should be covering. If we get reimbursement, the patient population is huge."
Said Dr. Joel Boyd, an orthopedic surgeon who works with professional sports teams -- including the Minnesota Wild, the Minnesota Vikings and the Minnesota Lynx -- and has used the device on his own knees: "You need to have insurance companies sign off on it. If you don't, I need to have my patients pay for this."
Thom Gunderson, an analyst with Piper Jaffray & Co., said reimbursement is the third leg of the stool for any successful medical device -- one that sometimes gets overlooked. And, he said, "payers are historically and notoriously slow in paying for new technologies. You have to show them it's in their best interest to do this."